Eikon Therapeutics, Inc. EIKN
—
7.92
(0.37)
(4.46%)
as of 25 Sep
- Market cap
- $449.0M
- P/E
- 0.0×
Follow EIKN
Insider Buys
alert about insiders buying in the last 12 month
| Dec '24 | Dec '25 | |
|---|---|---|
Current Ratio |
4.04 | 6.34 |
Net Debt/EBITDA |
0.94 | 1.07 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
0.55 | 0.57 |
Capex/Depreciation |
(3.34) | (1.93) |
Interest Coverage |
0.00 | 0.00 |
| 0.00% | 45.99% | |
| 0.00% | (61.45%) | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(78.12%) | (76.38%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(87.15) | (81.29) |
Cash per Share |
87.51 | 116.24 |
Shareholders Equity per Share |
(226.98) | (303.75) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(226.98) | (303.75) |
Free Cash Flow |
(219.60) | (235.26) |
Working Capital |
171.44 | 293.91 |
Capital Expenditures |
(84.80) | (46.74) |
Net Current Asset Value |
(835.28) | (1,124.85) |
| Other line items | ||
Quick Ratio |
3.91 | 6.12 |
Depreciation/Fixed assets |
0.18 | 0.17 |
Cash ROIC |
78.39% | 61.07% |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(53.50) | (65.14) |
Capex per Share |
(33.66) | (16.15) |
Average Payables |
— | 9.13 |
Average Assets |
— | 542.99 |
Average Common Equity |
— | (725.48) |
Capex to Sales |
0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% |
Columns are period end dates